A phase II trial of FUdR in patients with advanced pancreatic cancer

Journal of Cancer Research and Clinical Oncology

Volumn 130, Issue 10, 2004, Pages 561-566

  Ardalan, Bach ^a   Lima, Mayra ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; FUdR (Floxuridine); Survival; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; FLOXURIDINE; NARCOTIC ANALGESIC AGENT; SEROTONIN 3 AGONIST;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER PAIN; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEMALE; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER DYSFUNCTION; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SKIN MANIFESTATION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; FLOXURIDINE; HUMANS; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 5644258598     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-004-0584-5     Document Type: Article

References (22)

1. Acute Pain Management Guideline Panel (1992) Acute pain management: operative or medical procedures and trauma. Clinical practice guideline. Agency for Health Care Policy and Research, Public Health Service. U.S. Department of Health and Human Services. AHCPR 92-0032, Rockville, MD, USA
2. Ardalan B, Deng Z (1998) Comparison of cytotoxicity of fluoropyrimidines in human colon adenocarcinoma DLD-1 cells: with clinical implications. AACR 39:435
3. Ardalan B, Cooney D, MacDonald J (1980) Physiological and pharmacological determinants of sensitivity and resistance to 5-fluorouracil in lower animals and man. In: Garattini A, Hawking GF, Koplin IJ (eds) Advances in Pharmacology and Chemotherapy, vol. 17. Academic, New York, pp 289-321
4. Ardalan B, Ucar A, Reddy R, Livingstone AS, Markoe A, Schwade J, Richman SP, Donofrio K (1994) Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas. Cancer 74:1869-1873
5. Ardalan B, Livingstone A, Franceschi D, Sridhar KS, Feun LG, Richman SP, Tripplett N, Sparling L (1997) phase II trial of high dose 24 h infusion of fluorodeoxyuridine (FUdR) in patients with inoperable pancreatic cancer (previously failed 5-FU and Gemzar) (Abstract). Proc Am Soc Clin Oncol 16:282
6. Brennan MF, Kinsella TJ, Casper ES (1993) Cancer of the pancreas. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology (4th edn). Lippincott, Philadelphia, pp 849-882
7. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps C, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
8. Cullinan S, Moertel CG, Wieand HS, Schutt AJ, Krook JE, Foley JF, Norris BD, Kardinal CG, Tschetter LK, Barlow JF (1990) A phase III trial on the therapy of advanced pancreatic carcinoma: evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 65:2207-2212
9. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Wind HE, Twito I, Marschke RF, Foley JF (1985) A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 253:2061-2067
10. Heinemann V, Quietzsch D, Geisler M, Gonnermann H, Schonekas A, Rost H, Neuhaus C, Haag C, Stoffregen M, Clemens (2003) A phase III trial comparing gemcitabine plus cisplatin vs gemcitabine alone in advanced pancreatic cancer. Proc ASCO 22 [abstr 1003]
11. Karnofsky BA, Abelmann WH, Graver LF, Burchenal L (1948) The use of nitrogen mustards in the palliative treatment of cancer. Cancer 1:634-656
12. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Magalik A, Macdonald JS (1995) phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncol 13:1303-1311
13. Louvet C, Labianca R, Hammel G, Lledo F, DeBraud T, Andre M, Cantore M, Ducreux A, Zaniboni A, DeGramont E (2003) gemcitabine vs GEMOX (gemcitabine + oxaliplatin) in non-resectable pancreatic adenocarcinoma: interim results of the GERCOR/GISCAD Intergroup phase III. Proc ASCO 22 [abstr 1004]
14. Mallinson CN, Rake MO, Cocking JB, Fox CA, Cwynarski MT, Diffey BL, Jackson GA, Hanley J, Wass VJ (1980) Chemotherapy in pancreatic cancer: results of a controlled prospective, randomized, multicenter trial. BMJ 218:1589-1591
15. Moertel CG, Engstrom P, Lavin PT (1979) Chemotherapy of gastric and pancreatic carcinoma: a controlled evaluation of combinations of 5-fluorouracil with nitrosoureas and "lactones". Surgery 85:509-513
16. O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller DG, Arbuck SG, Weiner LM, Mayer RJ, Benson AB 3rd (2001) Fluorouracil modulation in colorectal cancer: lack of improvement with N-phosphonoacetyl-1 - aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule. An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol 19:2413-21
17. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 4:649-655
18. Rocha-Lima C, Rotche R, Jeffery M, Trudeau LA, Cisar A, Morganti G, Gruia L, Miller MR, Green MR (2003) A randomized phase 3 study comparing the efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy. Proc ASCO 22 [abstr 1004]
19. Tian E, Donofrio K, Sridhar KS, Feun LG, Morrell L, Richman SP, Benedetto P, Chatoor H, Ardalan B (1994) Phase I study of 24 hr infusion of 5-fluoro-deoxyuridine (FUdR) with pharmacokinetics. AACR 35:244
20. Ucar A, Ardalan B, (1993) Biochemical modulation of fluoropyrimidines. J Infusional Chemother 3:174-183
21. Warshaw AL, Fernandez-del Castillo C (1992) Pancreatic carcinoma. N Engl J Med 326:455-465
22. World Health Organization (1979) World handbook for reporting results of cancer treatment. WHO, Geneva